Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effe...
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
- Associated Therapies
- -
Detoxification From the Lipid Tract
- Conditions
- Interventions
- Device: electroencephalogram biofeedbackDevice: electrical brain stimulationDevice: ultra-low frequency transcranial magnetic stimulationDrug: Sertraline HydrochlorideDrug: ClonazepamDrug: AlprazolamDrug: MetoprololDrug: OlanzapineDrug: Pravastatin Sodium 20 MGDrug: Sacubitril Valsartan Sodium Hydrate
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Pachankis, Yang I., M.D.
- Target Recruit Count
- 1
- Registration Number
- NCT06357104
- Locations
- 🇨🇳
Residential Address, Chongqing, Chongqing, China
Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 45
- Registration Number
- NCT06293638
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 100
- Registration Number
- NCT05602818
- Locations
- 🇺🇸
Altasciences, Overland Park, Kansas, United States
Opioid/Benzodiazepine Polydrug Abuse: Aim 3
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 24
- Registration Number
- NCT05006079
- Locations
- 🇺🇸
Tolan Park Medical Building, Detroit, Michigan, United States
A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 14
- Registration Number
- NCT04857307
- Locations
- 🇺🇸
Up0100 105, Memphis, Tennessee, United States
🇺🇸Up0100 103, Honolulu, Hawaii, United States
🇺🇸Up0100 106, Cincinnati, Ohio, United States
A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 78
- Registration Number
- NCT04802746
- Locations
- 🇺🇸
Up0099 102, Raleigh, North Carolina, United States
🇺🇸Up0099 101, North Dartmouth, Massachusetts, United States
Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 30
- Registration Number
- NCT04782388
- Locations
- 🇺🇸
Up0101 101, Anaheim, California, United States
Role of Alprazolam in the Management of Acute Coronary Syndrome
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Sohaib Ashraf
- Target Recruit Count
- 48
- Registration Number
- NCT04715269
- Locations
- 🇵🇰
Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan
Assessment of Effect of Rapastinel on Driving Performance
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Target Recruit Count
- 107
- Registration Number
- NCT03814733
- Locations
- 🇺🇸
Collaborative Neuroscience Network, San Clemente, California, United States
🇨🇦Algorithme Pharma, Aurora, Ontario, Canada
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Per-Ola Carlsson
- Target Recruit Count
- 35
- Registration Number
- NCT03635437
- Locations
- 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.